Herriot Tabuteau, Axsome Therapeutics CEO
Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat
Axsome Therapeutics said the lower dose of its sleep disorder drug Sunosi met the primary endpoint in a late-stage test of adults with ADHD. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
